Cargando…

Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer

The development of targeted therapies increases treatment options for metastatic castration resistant prostate cancer (mCRPC) patients. There is a need for strong predictive and prognostic signatures to guide physicians in treating mCRPC patients. In this review we unravel the possible actionability...

Descripción completa

Detalles Bibliográficos
Autores principales:	Devlies, Wout, Eckstein, Markus, Cimadamore, Alessia, Devos, Gaëtan, Moris, Lisa, Van den Broeck, Thomas, Montironi, Rodolfo, Joniau, Steven, Claessens, Frank, Gevaert, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698403/ https://www.ncbi.nlm.nih.gov/pubmed/33212909 http://dx.doi.org/10.3390/cells9112494

Ejemplares similares

Preclinical Models in Prostate Cancer: Resistance to AR Targeting Therapies in Prostate Cancer
por: Devlies, Wout, et al.
Publicado: (2021)

Double trouble for prostate cancer: synergistic action of AR blockade and PARPi in non-HRR mutated patients
por: Giesen, Alexander, et al.
Publicado: (2023)

FRI475 The Impact Of Suppression Of Androgen Signaling On Thyroid Hormone Homeostasis In Prostate Cancer Patients
por: David, Karel, et al.
Publicado: (2023)

PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What’s Now, What’s New, and What’s Coming?
por: Marchetti, Andrea, et al.
Publicado: (2022)

Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer
por: Di Nunno, Vincenzo, et al.
Publicado: (2018)

Changes in bone and mineral homeostasis after short-term androgen deprivation therapy with or without androgen receptor signalling inhibitor – substudy of a single-centre, double blind, randomised, placebo-controlled phase 2 trial
por: David, Karel, et al.
Publicado: (2023)

PREDICT Prostate, a useful tool in men with low- and intermediate-risk prostate cancer who are hesitant between conservative management and active treatment
por: Devos, Gaëtan, et al.
Publicado: (2020)

Comparison of Peri-operative and Early Oncological Outcomes of Robot-Assisted vs. Open Salvage Lymph Node Dissection in Recurrent Prostate Cancer
por: Devos, Gaëtan, et al.
Publicado: (2019)

An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT
por: Mollica, Veronica, et al.
Publicado: (2021)

Update on Prostate Cancer Diagnosis, Prognosis, and Prediction to Response to Therapy
por: Montironi, Rodolfo, et al.
Publicado: (2020)

Digital diagnostics and artificial intelligence in prostate cancer treatment in 5 years from now
por: Cimadamore, Alessia, et al.
Publicado: (2021)

The Identification of Immunological Biomarkers in Kidney Cancers
por: Lopez-Beltran, Antonio, et al.
Publicado: (2018)

Metastasis-directed therapy in castration-refractory prostate cancer (MEDCARE): a non-randomized phase 2 trial
por: Berghen, Charlien, et al.
Publicado: (2020)

The Genomic Landscape of Prostate Cancer
por: Spans, Lien, et al.
Publicado: (2013)

Comparing the expression profiles of steroid hormone receptors and stromal cell markers in prostate cancer at different Gleason scores
por: Gevaert, Thomas, et al.
Publicado: (2018)

Bone Targeting Agents in Patients with Metastatic Prostate Cancer: State of the Art
por: Mollica, Veronica, et al.
Publicado: (2021)

The potential of tumour microenvironment markers to stratify the risk of recurrence in prostate cancer patients
por: Gevaert, Thomas, et al.
Publicado: (2020)

Conceptual Analogies Between Multi-Scale Feeding and Feedback Cycles in Supermassive Black Hole and Cancer Environments
por: Santoni, Matteo, et al.
Publicado: (2021)

Risk stratification tools in prostate cancer, where do we stand?
por: Clinckaert, Andries, et al.
Publicado: (2021)

Drivers of AR indifferent anti-androgen resistance in prostate cancer cells
por: Handle, Florian, et al.
Publicado: (2019)

Comparative Genomic and Transcriptomic Analyses of LNCaP and C4-2B Prostate Cancer Cell Lines
por: Spans, Lien, et al.
Publicado: (2014)

The Current Landscape of Treatment in Non-Metastatic Castration-Resistant Prostate Cancer
por: El-Amm, Joelle, et al.
Publicado: (2019)

Treatment Landscape for Metastatic Castrate-Sensitive Prostate Cancer: A Review
por: Meagher, Margaret F, et al.
Publicado: (2023)

Penile metastasis in prostate cancer patients: Two case reports, surgical excision technique, and literature review
por: Landen, Lucas, et al.
Publicado: (2023)

Editorial: Emerging Biomarkers in Genitourinary Tumors
por: Montironi, Rodolfo, et al.
Publicado: (2019)

Uropathologists During the COVID-19 Pandemic: What Can Be Learned in Terms of Social Interaction, Visibility, and Social Distance
por: Montironi, Rodolfo, et al.
Publicado: (2020)

Lesson from the COVID-19 pandemic: pathologists need to build their confidence on working in a digital microscopy environment
por: Montironi, Rodolfo, et al.
Publicado: (2021)

The changing landscape in the management of newly diagnosed castration sensitive metastatic prostate cancer
por: Parker, Daniel C., et al.
Publicado: (2020)

The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited
por: Deek, Matthew P., et al.
Publicado: (2021)

Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer
por: Montironi, Rodolfo, et al.
Publicado: (2020)

Prostate Cancer in 2021: Novelties in Prognostic and Therapeutic Biomarker Evaluation
por: Cimadamore, Alessia, et al.
Publicado: (2021)

Emerging Prognostic Biomarkers in Testicular Germ Cell Tumors: Looking Beyond Established Practice
por: Chovanec, Michal, et al.
Publicado: (2018)

The Role of Single Nucleotide Polymorphisms in Predicting Prostate Cancer Risk and Therapeutic Decision Making
por: Van den Broeck, Thomas, et al.
Publicado: (2014)

Obesity and prostate cancer research
por: Van den Broeck, Thomas, et al.
Publicado: (2013)

Narrative review: predicting future molecular and clinical profiles of prostate cancer in the United States
por: Santoni, Matteo, et al.
Publicado: (2021)

Narrative review of prostate cancer grading systems: will the Gleason scores be replaced by the Grade Groups?
por: Montironi, Rodolfo, et al.
Publicado: (2021)

Long Non-coding RNAs in Prostate Cancer with Emphasis on Second Chromosome Locus Associated with Prostate-1 Expression
por: Cimadamore, Alessia, et al.
Publicado: (2017)

Molecular Classification of Bladder Urothelial Carcinoma Using NanoString-Based Gene Expression Analysis
por: Lopez-Beltran, Antonio, et al.
Publicado: (2021)

New Prostate Cancer Targets for Diagnosis, Imaging, and Therapy: Focus on Prostate-Specific Membrane Antigen
por: Cimadamore, Alessia, et al.
Publicado: (2018)

Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer
por: Fallara, Giuseppe, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tdk2tjugka477shgt985sbjmj0